TG Therapeutics appoints Kenneth Hoberman to board
This article was originally published in Scrip
Executive Summary
New York-based TG Therapeutics, a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases, has named Kenneth Hoberman to its board of directors. Mr Hoberman is currently the chief operating officer of Stemline Therapeutics and was formerly the vice-president of corporate and business development at Keryx Biopharmaceuticals.